Gene expression signatures in early breast cancer: Better together with clinicopathological features

Breast cancer (BC) is a highly heterogeneous disease, characterized by a variety of subtypes with distinct biological, molecular, and clinical behavior. Standard clinicopathological and tumor biology information (as assessed by gene expression signatures-GES), have provided enhanced prognostic and predictive information in both node-negative(N0) and positive(N +), hormonal receptor positive/human epidermal growth factor 2 negative (HR+/HER2-) early breast cancer (EBC). Herein, we comprehensively review the clinical data of 5 commonly used GES, namely, Oncotype DX(ODX)(R); MammaPrint (MP)(R); Prosigna (R); Breast Cancer Index (BCI) (R) and Endopredict (R) - with sections specifically addressing the role of GES in special histologic subtypes, premenopausal women, late recurrence and adjuvant treatment de-escalation.

Automated summary

We comprehensively review the clinical data of 5 common gene expression signatures (GES) in breast cancer, discussing their roles in special histologic subtypes, premenopausal women, late recurrence, and adjuvant treatment de-escalation.